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Trefoil Factor 1 (TFF1) Expression in E3 and EWD8 Breast Cancer Cell Lines
Jazmyn Mosqueda
Mentor: Nicholas Pullen, Ph.D., Biological Sciences
Abstract: The ability to identify and treat cancer early can drastically improve patient survival outcomes. While
much effort is placed on anti-cancer therapeutics, a developing area of interest is the identification of cancer
biomarkers for the early detection of different types of cancer. Trefoil factors (TFFs) are a family of proteins
whose known functions suggest that they may be major contributors to cancer; however, these proteins are
understudied in a disease state like cancer. In this work, we identify expression of TFF1 among varying cancer
types. We then investigate the correlation between varying levels of TFF1 expression and the aggressiveness of
the cancer. Cell culture of seven different kinds of cancers was performed. Western blots were conducted, and the
blots were probed for TFF1. After establishing TFF1 levels, we aimed to analyze cancer cell function through a
series of cancer assays examining proliferation, viability, and migration. We hypothesized that there would be
varying levels of TFF1 expression correlated to the functional characteristics of the cancer cells, and that
increased levels of TFF protein would support a more aggressive cancer. The breast cell lines tested were the only
lines to express TFF1 and were less aggressive than the lines with no expression.
Keywords: cancer biomarkers, oncogenes, trefoil, tumor suppressors

Cancer is a detrimental disease associated
with aging; as life expectancy rises so does the
risk of getting cancer. Globally, an estimated one
in three women and one in two men will develop
cancer in their lifetimes1. Cancer is characterized
by uncontrollable cell growth that gains resistance
to death signals, increasing pro-survival
mechanisms of the cancerous cell and its
properties2. Although cancer treatments have
caused survival rates to increase, there is a
demand for viable biomarkers for the many types
of different cancers. A viable biomarker is
indicative to the presence of cancer within the
body and helps diagnose patients promptly.
Trefoil factors (TFFs) are secreted proteins
that help in healing epithelial tissue in the
stomach3, thus have the potential to be biomarkers
in many types of cancers. The normal function of
TFFs is to regulate cell growth and assist cells in
recognizing environmental stress that leads to
inflammation. While TFFs are an attractive cancer
biomarker, further investigation of cancer cell
function in the context of TFF expression could
also provide information on the plausibility of
TFFs as treatment targets. Further research on
TFFs is required to understand their expression
and function in cancerous cells. The need for this
research is not only to better understand TFFs in

Published by Scholarship & Creative Works @ Digital UNC, 2019

cancers but hopefully to identify a new source of
markers for detecting cancer in its earlier stages,
and therefore mitigate aggressive and potentially
intractable metastic disease.
In this study, we aimed to identify the levels
of TFF1 expression in cancerous cells that have
not been investigated for the family of proteins.
We then correlated the varying levels of
expression to the aggressiveness of the cancer.
We hypothesized that there would be varying
amounts of TFF1 expression due to the functional
characteristics of the cancer cells. We also
expected that increased levels of TFF1 would be a
form of support for a more aggressive cancer. We
found that the breast cell lines tested were the
only lines to express the protein and were actually
less aggressive than the lines with no TFF1
expression.
LITERATURE REVIEW
Cancer is one of the largest epidemics in our
world. In 2012, an estimated 14 million new cases
of cancer and 8.2 million cancer-related deaths
were documented world-wide2. Early detection
and prevention of cancer has become just as
paramount a concern as treatment, leading many
to investigate new possible biomarkers for the
disease. Cancer markers are substances naturally

1

Ursidae: The Undergraduate Research Journal at the University of Northern Colorado, Vol. 7, No. 2 [2019], Art. 6

produced by the body, and when cancer is present
these substances are produced at different levels2.
TFFs are proteins secreted by epithelial cells
primarily for wound healing in mucosal
membranes, which makes its investigation as a
biomarker attractive3. The proteins are named
after a trefoil motif structure composed of
disulfide loops5. There are three TFFs: TFF1,
TFF2 and TFF3. TFF1, previously known as pS2,
was first found in breast cancer, and TFF2 was
extracted and purified from the pancreas6-7.
Intestinal trefoil factor, now TFF3 was later found
in both intestines8. This family of proteins has
similar characteristics but vary in expression and
function throughout the body9.
The stomach is the only organ in which all
three TFFs are expressed9. TFF1 expression is
highest in the stomach and colon, while TFF2
levels are highest in the stomach, and TFF3 levels
are highest in the colon9. Other studies have
looked at particular parts of the body and cancer
cells located within those parts (e.g., gastric and
breast) to determine TFF expression11-20. Recent
studies have found TFF expression may lead to
detection of various cancers21-24. TFF proteins are
gaining recognition as cancer biomarkers in the
field. The purpose of this literature review is to
investigate TFF expression in different cancers
and identify their likelihood as biomarkers.
Trefoil Factors in Gastric Cancer
Gastric cancer is the fifth most common
cancer world-wide, accounting for almost 1,000
of the new cancer cases in 201210. There are
known classic biomarkers for gastric cancer but
TFFs may be novel markers for the disease11.
TFF1 expression is essential for gastric mucosa
cells to differentiate12. When expression of TFF1
is low, gastric adenomas can develop and a
percentage of the tumors can become cancerous12.
Low expression of TFF1 in the gastric mucosa
could show signs for early detection of stomach
adenoma carcinoma, but the opposite could be
true for TFF3.
TFF3 expression levels are typically low in
gastric mucosa, but it is overexpressed in gastric
cancer13. High TFF3 expression could be an
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effective biomarker for gastric cancer. In one
study, 90 gastric cancer patients provided blood
and urine samples that were examined for TFF3
levels14. TFF3 levels were significantly higher in
the serum and urine of cancer patients compared
to the healthy individuals. These higher levels
correlated with the advancement of the stages as
well as the distance of metastasis. The authors
concluded that TFF3 serum could be a biomarker
for gastric cancer in detecting tumor stages and in
identifying metastases. Overexpression of TFF3
in gastric cancer has led researchers to consider
that it has potential as a cancer marker, and the
same may be true for TFF215.
TFFs appear to be regulated on their own, but
in some cases other proteins or substances help
mediate their regulation. Sp3 protein was found to
be an essential binding partner to TFF2, which
mediates the biological functions of the protein in
gastric cancer cells15. Overexpression of the two
proteins suppressed cell proliferation and induced
apoptosis of the cancer cells and significantly
lowered cell invasion as well. These findings
showed that Sp3 is needed to regulate TFF2 and
together their overexpression (or their absence)
could make for cancer markers15.
Trefoil Factors in Breast Cancer
Breast cancer is the most common cancer
among women and the second most common
cancer world-wide10, and it is well established that
TFFs are expressed in MCF-7 breast cancer cell
lines16. In a study that used knockdown TFF1 in
MCF-7 cells, the effects of estrogen with
doxorubicin treatment were tested17. The cells that
started with a low expression of TFF1 had
upregulated expression after being transfected.
The proteins expressed pro- or anti-apoptotic
properties, which led the authors to the idea that
TFF1 has a role in the apoptotic status of the cells.
The authors made connections that estrogen
inhibits the actions of doxorubicin and that TFF1
can play a role in allowing estrogen to do this17.
Kannan et al. used MCF-7 and T47D cells
transfected with TFF3 to determine TFF function
and relationship with estrogen18. TFF3 was
identified as a novel growth factor in breast
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cancer. Forced expression of this gene enhanced
oncogenesis. Estrogen regulates TFFs and
protects MCF-7 breast cancer cells from death.
Together, estrogen and TFF expression can be a
viable biomarker for breast cancer17-18.
Ahmed et al. investigated TFF3 expression in
normal breast cancer cells, benign breast tumors
and in situ carcinomas19. In the normal breast
tissues, TFF3 protected the epithelial tissue, but
TFF3 expression was lost in invasive breast
cancers. TFF3 expression was also restricted at
certain times during a woman’s menstrual cycle.
TFF3 was found to have a negative relationship
with tumor grade for the cancers studied, but
could better differentiate the type of tumor. The
authors found that TFF3 stimulates angiogenesis
in the cancer cells. The authors also stated that in
vitro studies of this kind would help back up their
claim that TFF3 may be a prognosis marker. May
and Westley evaluated TFF3 as a biomarker and
noted the response of this protein in breast cancer
cells20. Human TFF3 was transfected into breast
cancer tissues from patients that underwent
endocrine response therapy. Tumors with high
TFF3 levels had evenly distributed expression
compared to tumors with lower TFF3 levels,
which had sparse expression. This pattern could
be due to the amount of estrogen present in the
body or the woman’s menstrual cycle as stated
previously19. The authors concluded that TFF3
expression might work as an independent
predictive biomarker for estrogen and be specific
and sensitive as a marker in breast cancer.
Trefoil Factors in Other Cancers
There are over 100 types of known cancers2,
and only a few forms of cancer have been studied
for TFF expression. Prostate cancer, endometrial
adenocarcinoma (EAC), and lung adenocarcinoma
have been investigated for TFF expression,
including their possible roles as biomarkers for
these specific cancers21. In prostate cancer, forced
expression of TFF1 was shown to decrease ECADHERIN (protein) expression leading to an
increase of metastases and invasion of the cancer
cells, both in vivo and in vitro. In vivo, the cells
invaded and metastasized at an increased rate. The
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authors concluded that overexpression of TFF1
could be a biomarker for prostate cancer and
determine tumor metastasis or tumor burden. In
this study, E-CADHERIN transcription was
mediated by TFF1; however, as stated before
estrogen or estrogen receptor (ER) have different
roles in mediating TFF expression21.
Estrogen levels have been found to correlate
with TFF levels in many breast cancer studies.
Like in breast cancer, the combination of ER and
TFF can make for a specific marker in uterine
cancer22. In EAC it has been confirmed that high
levels of ER lead to good prognosis for the
cancer22. Mhawech et al. aimed to evaluate TFF3
expression and prognosis as well as look at its
relationship with ER22. High levels of TFF3
corresponded with those of ER, providing
evidence that TFF3 and ER lead to better tumor
outcomes. TFF3 could possibly stand alone as a
biomarker for EAC patients, but additional
investigation is needed to support this. The
authors suggested further research of knockdown
TFF3 in EAC to determine its role in
proliferation, migration and invasion of tumors
and as a cancer marker22. Identified biomarkers
for uterine cancer exist, but TFFs can be
compared to the cancers to analyze their
effectiveness and expression.
Lung cancer is the deadliest and most
common cancer worldwide, which compels the
need for biomarkers for early onset detection.9.
Wang et al. studied the expression of established
biomarkers TTF-1, CK7, P63 and CK5/6 in lung
adenocarcinoma and squamous cell carcinoma
and compared their expression patterns to those of
TFF323. In comparison to the established markers,
TFF3 had a 90% expression pattern in lung
adenocarcinoma. The authors found higher levels
of TFF3 in the cancer cells, which varied in the
amount of expression between the cell lines, and
TFF3 played a role in differentiating the cells.
Lastly, the authors concluded that TFF3 is all
around “more sensitive” as a biomarker for all
organs, not just specific organs compared to the
established biomarkers23. This study showed that
TFF3 has the potential of being a biomarker when
compared to established markers.

3

Ursidae: The Undergraduate Research Journal at the University of Northern Colorado, Vol. 7, No. 2 [2019], Art. 6

Conclusion
Cancer treatment has progressed, allowing
researchers and physicians to get the five-year
survival rate up to 66%; yet, there is more that can
be done to raise this percentage9. Earlier detection
of the disease can lead to better prognosis, and
lower the amount of cancer-related deaths. TFF
proteins have the potential to be biomarkers in
many types of cancers. The expression levels of
these proteins could identify various cases of early
onset cancer or the amplitude of metastases. Many
cancers are left to be investigated for TFF
expression. We looked at breast cell lines MCF-7,
E-3, EWD-8, skin A375, lung A549, colon
COLO205 and mast cell lines P815 for TFF1
expression. We expected varying levels of TFF1
expression correlated to the functional
characteristics of the cancer cells, and that
increased levels of TFF protein would support a
more aggressive cancer. TFFs may be viable
biomarkers that can aid in the early prognosis of
cancer that in turn may lead to the use of less
invasive and detrimental forms of cancer
treatment. Further investigation of these proteins
as biomarkers is also necessary.
METHODS
Cell Culture
Breast MCF-7, E3 and EWD8, skin A549,
lung A375, colon COLO205 and mast P815 cells
were cultured in 10cm diameter dishes and T75
cell culture flasks (VWR, Radnor, PA)
Dulbecco’s Modified Eagle Medium (DMEM,
Thermo Fisher Scientific, Waltham, MA). The
culture medium was supplemented with
(%volume) 10% equine and fetal bovine serum
mixture (FBE from VWR), and 2mM Lglutamine, 1mM sodium pyruvate, 0.01M
HEPES, and 1 unit/mL penicillin/streptomycin
mixture (all from Thermo Fisher Scientific). Cells
were enzymatically passaged with trypsin-EDTA
(Thermo Fisher Scientific) when the bottom of the
plate was fully covered by the cancerous cells.
Since trypsin passaging can epigenetically
influence cells over many passages, low passage
number samples were used from liquid nitrogen
storage.
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Protein Isolation and Concentration
Measurements
Approximately 35000ml of cells from a
passage were placed into six well plates and
allowed to grow over 3 days. For cell lysis, plate
was put on ice and 100µl of 1X Lysis Buffer (Cell
Signaling Technology, Danvers, MA), with
protease inhibitors leupeptin and orthovanadate,
was added to each well. After lysis and of proteins
into the buffer for 10-15min the mixture was
centrifuged at 14,000xg for 10min to separate
leftover cell/organelle membrane fractions from
solubilized proteins. The supernatant, which
contains intracellular proteins like TFFs, was kept
to measure protein concentration. A Nanodrop
2000 device was used to measure protein
concentrations from the samples.
SDS-PAGE and Immunoblotting
Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) followed by
immunoblotting was conducted on cell lysates and
replicated to detect TFF expression in the cells.
Equal quantities of total protein from each sample
were loaded based on Nanodrop concentration
data. The gel tank was set up using a 1X TrisGlycine Running Buffer system. A size
standardized ladder and samples were loaded into
a 4%-20% polyacrylamide, Tris-Glycine gels and
resolved according to manufacturer’s instructions
(BIO-RAD, Hercules, CA). Once the proteins
separated, the gel was transferred to a stable
nitrocellulose blot using BIO-RAD’s Transblot
Electrode apparatus according to manufacturer’s
protocol. Using Ponceau S, we observed for equal
loading in each blot. Next, a standard primary
blocking buffer of Tris-Buffered Saline, 0.1%
(v/v) Tween-20 (TBS-T), 5% (v/v) bovine serum
albumin was used to block non-specific protein
binding by incubating with the blots at ambient
temperature for 1h with gentle agitation. After
blocking rabbit anti-human TFF1 (1:1000 dilution
factor in block buffer; Cell Signaling Technology)
was added to each blot, which were incubated
overnight with gentle agitation at 4oC. The
following day an anti-rabbit secondary antibody
(1:5000 dilution; LI-COR Biosciences, Lincoln,
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NE) solution of TBS-T, 5% (v/v) non-fat dry milk
was added to the blot after removing the primary
and rinsing with TBS-T. Blots were incubated
with the secondary antibody solution for 1h at
ambient temperature with gentle agitation.
Secondary incubation was followed by rinsing
with TBS-T. The secondary antibody has a horse
radish peroxidase (HRP) enzyme attached to it;
therefore, the blot was developed using a
chemiluminescent HRP substrate detection
reagent (WesternSure, LI-COR) and scanned with
the LI-COR cDigit device.
Migration Assay and Daily Count
A scratch test was conducted to assess the
migration of each cell line. Approximately
50000ml of cells was added to 10cm plate and
allowed to settle and cover the plate. The cells
were then scratched with a 200 L pipette tip, and
pictures were taken over time. Images were taken
daily until the scratch completely closed. ImageJ
(NIH, Bethesda, MD) was used to obtain the
surface area of the scratch from each image. Daily
counts for every cell line was also done to assess
growth rate, by adding 20µl of cells into 6-well
plates and counting one well per day. Trypsin was
added to lift the cells and then counted with Life
Technologies Countess II (Carlsbad, CA).

expressed the highest amount of TFF. Cell line E3
expressed the second highest amount of TFF and
EWD8 expressed the lowest amount, yet the ratio
was much smaller than 1 (MCF-7) for these cell
lines (Fig 2). From the scratch tests MCF-7, E3
and EWD8 appear to migrate the slowest (Fig. 3)
E3 on average took eight days to close the scratch
made, MCF-7 took an average of five days to seal
the closure, and EWD8 averaged six days. Cell
line A549 that did not express TFF1, on average
closed the scratch in two days. Daily cell count
for each cell type showed that MCF-7, E3 and
EWD8 cell lines had lower proliferation rates
compared to the cell lines that did not express
TFF1. At the end of the six-day count cell
concentration was 51,700 cells/mL for MCF-7,
39,400 for E3 cells/mL and 2,090,000 cells/mL
for EWD8 (Fig. 4).
Figure 1. A) TFF expression is shown through
Western blot. MCF-7 expressed the most protein
overall. B) Ponceau S staining of the blots was done to
ensure equal loading among each cell line.

MCF-7

E3

EWD8

A

Statistical Analysis
A qualitative approach was taken to observe
for the presence of bands indicating the presence
of TFF1 among each cell line. Descriptive
statistics were used to compare TFF1 expression
from cell type to cell type by taking the pixel
density average of MCF-7 and using it to take a
ratio for the other cell lines average expression.
Using ImageJ the surface area was averaged from
each scratch for each cell line.

B

RESULTS
After running Westerns blots, we found that
only three of the seven cell lines tested expressed
TFF1 (Fig. 1A) Equal loading of the protein was
assured through Ponceau S staining (Fig. 1B).
Breast MCF-7 was used as our positive control for
TFF1 expression. Breast E3 and EWD8 cell lines
also expressed the protein. MCF-7 on average
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Figure 2. Pixel density was taken from the blots. The values were averaged and a ratio was taken from the
average of MCF-7 expression. E3 and EWD8 expressed TFF protein.

Figure 3. Cell migration over time is shown after scratch tests were performed. Three scratches were made in
10ml petri dishes after the cells had completely covered the surface for each cell line expect P815 because of their
floating properties. ImageJ was used to obtain the surface area of the scratches from each image. MCF-7, E3 and
EWD8 appear to have migrated the slowest.
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Figure 4. Daily count of each cell was done. Counting for every cell line was done by adding 20µl of cells into 6well plates and counting one well per day using the trypan blue exclusion method and a Life Technologies
Countess II device. Cells that did not express TFF proliferated more than those who expressed it such as MCF-7,
E3 and EWD8.
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DISCUSSION
Our results show that only three of the seven
total cell lines tested had TFF1 protein expression
including the positive control. We predicted that
there would be varying levels of TFF1 among the
cell lines because of their morphological
characteristics. All three of our breast cell lines
MCF-7, E3 and EWD8 expressed TFF1 protein;
this may be due to their luminal breast cancer
characteristics. TFFs are well known for being
expressed in MCF-7 breast cancer cell lines3, and
on average MCF-7 expressed the highest amount
of TFF1. E3 expressed the second highest amount
of TFF1, and EWD8 expressed the lowest
amount. As previously stated estrogen appears to
mediate TFF expression17-20. MCF-7 and cell lines
E3 express estrogen receptor while EWD8 cell
lines are estrogen-withdrawn cell lines27. This
may explain why MCF-7 and E3 expressed more
TFF1 than the EWD8s. EWD8 may be
regenerating estrogen or have estrogen strands left
over that would cause the low but present TFF1
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expression. Treating the cells with estrogen and
progesterone may have significant changes on the
cell’s TFF expression and is worth considering.
Previous research has found that
overexpression of TFFs can be used as a possible
biomarker for certain cancers. We also
hypothesized that the cancer would be more
aggressive if more TFF1 was present (i.e., faster
growth rate, faster scratch closure), but our
current observations showed the opposite pattern.
Further assays suggested that these cells grow as
slow as the positive control (MCF-7) compared to
the other cell lines, among which we did not
detect any TFF1 expression. The cell lines
expressing TFF1 on average took a longer time to
close the scratch test. Daily counting provided
more evidence that there were lower rates of
proliferation on average in the breast cell lines.
TFFs have been found to be biomarkers and to
have oncogenic or tumor suppressing effects
among many cancers10-13. Some have correlated
high TFF expression with aggressive cancers
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across different phenotypes, thus indicating their
promise as a cancer biomarker. There is also the
possibility that TFF are a side effect from the
cancer, rather than direct oncogenes, yet further
research is required.
A limitation to this study was only probing for
one of the three TFF proteins. We plan to adjust
our protocol in order to probe for the TFF2 and
TFF3 antibodies. Our data suggested that the
more TFF present the less aggressive the cancer
suggesting it can be used as a possible target
treatment for aggressive cancers. Next steps
would be to treat one of the more aggressive cell
lines, like lung A549 with recombinant TFF and
observe for any changes in the cancers
aggressiveness. Since cell lines MCF-7, E3 and
EWD8 expressed TFF1, we also plan to use genesilencing techniques, such as siRNA transfection
and/or CRISPR-Cas9, to edit the cells’ genomes
and remove the TFF1 protein. Thus, we plan to
observe what occurs in regards to the
aggressiveness of the cancer in the absence of the
specific TFF, in cell lines typically expressing the
TFF. We would expect the treated lung A549 cell
lines to become less aggressive, and the
knockdown-TFF1 cell lines MCF-7, E3 and
EWD8 to become more aggressive.
We originally predicted that TFF1 expression
would be associated with more aggressive cancer
cells but found the opposite pattern. The cancer
cell lines that expressed TFF1 were less
aggressive than those that did not which implies
that the loss of these proteins within these cancers
would lead to a cancer that is more aggressive.
While our results do not demonstrate what we
initially hypothesized, it is important to note that
TFFs may still be biomarkers for less aggressive
cancer types. High expression levels of TFFs
could allow for the detection of less aggressive or
early stages of aggressive cancers. Based on these
data and prospective clinical data what we would
expect to see less aggressive breast cancers
express higher levels of TFFs than more
aggressive cancers. TFFs continue to be debated
on whether they are tumor suppressors or
oncogenes as well as varying levels working as
biomarkers in many cancers, yet the proteins seem
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to have the potential to be viable cancer
biomarkers in less aggressive cancer settings from
our findings.
Identification of cancer biomarkers is essential
for the early detection of cancer to improve
patient survival outcomes. Treatment and therapy
is crucial in the fight against cancer, yet it comes
with many discomforts. Biomarkers would allow
for the early detection of the cancer that could
possibly lead to less invasive and aggressive
treatments. Further investigation would allow for
the categorization of TFF1 in these cancers as
oncogenic or tumor suppressors. TFF could also
possibly work as a treatment to suppress cancers.
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